(NASDAQ: HOWL) Werewolf Therapeutics's forecast annual revenue growth rate of 164.8% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 65.42%, and it is also forecast to beat the US market's average forecast revenue growth rate of 10.4%.
Werewolf Therapeutics's revenue in 2025 is $1,885,000.On average, 1 Wall Street analysts forecast HOWL's revenue for 2025 to be $268,962,954, with the lowest HOWL revenue forecast at $268,962,954, and the highest HOWL revenue forecast at $268,962,954. On average, 1 Wall Street analysts forecast HOWL's revenue for 2026 to be $2,241,357,950, with the lowest HOWL revenue forecast at $2,241,357,950, and the highest HOWL revenue forecast at $2,241,357,950.
In 2027, HOWL is forecast to generate $1,039,990,089 in revenue, with the lowest revenue forecast at $1,039,990,089 and the highest revenue forecast at $1,039,990,089.